Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Offidani

Showing results (121-130 of 149) with videos related to

Pageof 15
Sort By:
Haematologica|October 24, 2009
Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry studyLivio Pagano, Morena Caira, Anna Candoni, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 1, 2025
Cytogenetic Features and Their Implications in Clinical Practice: A Real-World Analysis of a Large Cohort of Multiple Myeloma PatientsSonia Morè, Massimo Offidani, Laura Corvatta, et al.
Journal of Cancer Research and Clinical Oncology|April 21, 2018
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysisChiara Cerrato, Francesco Di Raimondo, Lorenzo De Paoli, et al.
The Lancet. Oncology|December 17, 2015
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre studyMeletios A Dimopoulos, Philippe Moreau, Antonio Palumbo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 23, 2014
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survivalAntonio Palumbo, Sara Bringhen, Alessandra Larocca, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2011
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trialAntonio Palumbo, Michele Cavo, Sara Bringhen, et al.
Haematologica|March 1, 2013
Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trialsSara Bringhen, Maria Victoria Mateos, Sonja Zweegman, et al.
BMC Cancer|November 1, 2025
Supporting treatment decision-making for patients with multiple myeloma post-DRd in Italy: a multi-criteria decision frameworkMario Boccadoro, Angelo Belotti, Felice Bombaci, et al.
JAMA Oncology|August 12, 2018
Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysisFrancesca Gay, Graham Jackson, Laura Rosiñol, et al.
Annals of Hematology|November 8, 2020
Carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience of Rete Ematologica Pugliese (REP)Anna Mele, Eleonora Prete, Clara De Risi, et al.
Pageof 15

Showing results (121-130 of 149) with videos related to

Sort By:
Pageof 15
Haematologica|October 24, 2009
Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry studyLivio Pagano, Morena Caira, Anna Candoni, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 1, 2025
Cytogenetic Features and Their Implications in Clinical Practice: A Real-World Analysis of a Large Cohort of Multiple Myeloma PatientsSonia Morè, Massimo Offidani, Laura Corvatta, et al.
Journal of Cancer Research and Clinical Oncology|April 21, 2018
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysisChiara Cerrato, Francesco Di Raimondo, Lorenzo De Paoli, et al.
The Lancet. Oncology|December 17, 2015
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre studyMeletios A Dimopoulos, Philippe Moreau, Antonio Palumbo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 23, 2014
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survivalAntonio Palumbo, Sara Bringhen, Alessandra Larocca, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2011
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trialAntonio Palumbo, Michele Cavo, Sara Bringhen, et al.
Haematologica|March 1, 2013
Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trialsSara Bringhen, Maria Victoria Mateos, Sonja Zweegman, et al.
BMC Cancer|November 1, 2025
Supporting treatment decision-making for patients with multiple myeloma post-DRd in Italy: a multi-criteria decision frameworkMario Boccadoro, Angelo Belotti, Felice Bombaci, et al.
JAMA Oncology|August 12, 2018
Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysisFrancesca Gay, Graham Jackson, Laura Rosiñol, et al.
Annals of Hematology|November 8, 2020
Carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience of Rete Ematologica Pugliese (REP)Anna Mele, Eleonora Prete, Clara De Risi, et al.
Pageof 15